Canine tumors: a spontaneous animal model of human carcinogenesis

Gordon, 2010, Modeling opportunities in comparative oncology for drug development, ILAR J, 51, 214, 10.1093/ilar.51.3.214 Johnson, 2001, Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials, Br J Cancer, 84, 1424, 10.1054/bjoc.2001.1796 MacLeod, 1999, Widespread intraspecies cross-contamination of human tumor cell lines arising at source, Int J Cancer, 83, 555, 10.1002/(SICI)1097-0215(19991112)83:4<555::AID-IJC19>3.0.CO;2-2 Masters, 2002, HeLa cells 50 years on: the good, the bad and the ugly, Nat Rev Cancer, 2, 315, 10.1038/nrc775 Magalhães, 2009, Fut2-null mice display an altered glycosylation profile and impaired BabA-mediated Helicobacter pylori adhesion to gastric mucosa, Glycobiology, 19, 1525, 10.1093/glycob/cwp131 Richmond, 2008, Mouse xenograft models vs GEM models for human cancer therapeutics, Dis Model Mech, 1, 78, 10.1242/dmm.000976 Hansen, 2004, Spontaneous and genetically engineered animal models; use in preclinical cancer drug development, Eur J Cancer, 40, 858, 10.1016/j.ejca.2003.11.031 Simon, 2008, Lost in translation: problems and pitfalls in translating laboratory observations to clinical utility, Eur J Cancer, 44, 2707, 10.1016/j.ejca.2008.09.009 Schuh, 2004, Trials, tribulations, and trends in tumor modeling in mice, Toxicol Pathol, 32, 53, 10.1080/01926230490424770 Kim, 1994, Specific association of human telomerase activity with immortal cells and cancer, Science, 266, 2011, 10.1126/science.7605428 Prowse, 1995, Developmental and tissue-specific regulation of mouse telomerase and telomere length, Proc Natl Acad Sci U S A, 92, 4818, 10.1073/pnas.92.11.4818 Rangarajan, 2003, Opinion: comparative biology of mouse versus human cells: modelling human cancer in mice, Nat Rev Cancer, 3, 952, 10.1038/nrc1235 Teicher, 2009, In vivo/ex vivo and in situ assays used in cancer research: a brief review, Toxicol Pathol, 37, 114, 10.1177/0192623308329473 MacEwen, 1990, Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment, Cancer Metastasis Rev, 9, 125, 10.1007/BF00046339 Vail, 2000, Spontaneously occurring tumors of companion animals as models for human cancer, Cancer Invest, 18, 781, 10.3109/07357900009012210 Paoloni, 2007, Comparative oncology today, Vet Clin North Am Small Anim Pract, 37, 1023, 10.1016/j.cvsm.2007.08.003 Khanna, 2006, The dog as a cancer model, Nat Biotechnol, 24, 1065, 10.1038/nbt0906-1065b Paoloni, 2008, Translation of new cancer treatments from pet dogs to humans, Nat Rev Cancer, 8, 147, 10.1038/nrc2273 Kirkness, 2003, The dog genome: survey sequencing and comparative analysis, Science, 301, 1898, 10.1126/science.1086432 Lindblad-Toh, 2005, Genome sequence, comparative analysis and haplotype structure of the domestic dog, Nature, 438, 803, 10.1038/nature04338 Uva, 2009, Comparative expression pathway analysis of human and canine mammary tumors, BMC Genomics, 10, 135, 10.1186/1471-2164-10-135 Saal, 2007, Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity, Proc Natl Acad Sci U S A, 104, 7564, 10.1073/pnas.0702507104 Galanis, 2008, Reactive oxygen species and HIF-1 signalling in cancer, Cancer Lett, 266, 12, 10.1016/j.canlet.2008.02.028 Castaneda, 2010, The phosphatidyl inositol 3- kinase/AKT signaling pathway in breast cancer, Cancer Metastasis Rev, 29, 751, 10.1007/s10555-010-9261-0 Dillon, 2007, The phosphatidyl inositol 3- kinase signaling network: implications for human breast cancer, Oncogene, 26, 1338, 10.1038/sj.onc.1210202 Sweet-Cordero, 2005, An oncogenic KRAS2 expression signature identified by cross-species gene- expression analysis, Nat Genet, 37, 48, 10.1038/ng1490 Ressel, 2009, Reduced PTEN protein expression and its prognostic implications in canine and feline mammary tumors, Vet Pathol, 46, 860, 10.1354/vp.08-VP-0273-P-FL Cadigan, 1997, Wnt signaling: a common theme in animal development, Genes Dev, 11, 3286, 10.1101/gad.11.24.3286 Klaus, 2008, Wnt signalling and its impact on development and cancer, Nat Rev Cancer, 8, 387, 10.1038/nrc2389 Suzuki, 2008, Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer, Br J Cancer, 98, 1147, 10.1038/sj.bjc.6604259 Rao, 2008, cDNA microarray profiles of canine mammary tumour cell lines reveal deregulated pathways pertaining to their phenotype, Animal Genet, 39, 333, 10.1111/j.1365-2052.2008.01733.x Sebolt-Leopold, 2004, Targeting the mitogen-activated protein kinase cascade to treat cancer, Nat Rev Cancer, 4, 937, 10.1038/nrc1503 Chang, 2001, Clinical management of women with genomic BRCA1 and BRCA2 mutations, Breast Cancer Res Treat, 69, 101, 10.1023/A:1012203917104 Bièche, 1999, Overexpression of BRCA2 gene in sporadic breast tumours, Oncogene, 18, 5232, 10.1038/sj.onc.1202903 Maacke, 2000, Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer, Int J Cancer, 88, 907, 10.1002/1097-0215(20001215)88:6<907::AID-IJC11>3.0.CO;2-4 Thompson, 1995, Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression, Nat Genet, 9, 444, 10.1038/ng0495-444 Klopfleisch, 2009, Increased expression of BRCA2 and RAD51 in lymph node metastases of canine mammary Aden carcinomas, Vet Pathol, 46, 416, 10.1354/vp.08-VP-0212-K-FL Nieto, 2003, BRCA1 expression in canine mammary dysplasias and tumours: relationship with prognostic variables, J Comp Pathol, 128, 260, 10.1053/jcpa.2002.0631 Jerry, 2010, Estrogens, regulation of p53 and breast cancer risk: a balancing act, Cell Mol Life Sci, 67, 1017, 10.1007/s00018-009-0244-7 Klopfleisch, 2009, Differential expression of cell cycle regulators p21, p27 and p53 in metastasizing canine mammary adenocarcinomas versus normal mammary glands, Res Vet Sci, 87, 91, 10.1016/j.rvsc.2008.12.010 Lee, 2004, Mutation and overexpression of p53 as a prognostic factor in canine mammary tumors, J Vet Sci, 5, 63, 10.1292/jvms.66.63 Setoguchi, 2001, Aberrations of the p53 tumor suppressor gene in various tumors in dogs, Am J Vet Res, 62, 433, 10.2460/ajvr.2001.62.433 Ariazi, 2006, Estrogen receptors as therapeutic targets in breast cancer, Curr Top Med Chem, 6, 181, 10.2174/156802606776173483 Cordera, 2006, Steroid receptors and their role in the biology and control of breast cancer growth, Semin Oncol, 33, 631, 10.1053/j.seminoncol.2006.08.020 Howell, 2004, The use of selective estrogen receptor modulators and selective estrogen receptor down regulators in breast cancer, Best Pract Res Clin Endocrinol Metab, 18, 47, 10.1016/j.beem.2003.08.002 de Las Mulas, 2005, A prospective analysis of immunohistochemically determined estrogen receptor alpha and progesterone receptor expression and host and tumor factors as predictors of disease-free period in mammary tumors of the dog, Vet Pathol, 42, 200, 10.1354/vp.42-2-200 Geraldes, 2000, Immunohistochemical study of hormonal receptors and cell proliferation in normal canine mammary glands and spontaneous mammary tumors, Vet Rec, 146, 403, 10.1136/vr.146.14.403 Nieto, 2000, Immunohistologic detection of estrogen receptor alpha in canine mammary tumors: clinical and pathologic associations and prognostic significance, Vet Pathol, 37, 239, 10.1354/vp.37-3-239 Pinho, 2009, Molecular plasticity of E-cadherin and sialyl lewis x expression, in two comparative models of mammary tumorigenesis, PLoS One, 4, e6636, 10.1371/journal.pone.0006636 Baranwal, 2009, Molecular mechanisms controlling E-cadherin expression in breast cancer, Biochem Biophys Res Commun, 384, 6, 10.1016/j.bbrc.2009.04.051 Chang, 2005, Prognostic factors associated with survival two years after surgery in dogs with malignant mammary tumors: 79 cases (1998-2002), J Am Vet Med Assoc, 227, 1625, 10.2460/javma.2005.227.1625 Hellmén, 1993, Prognostic factors in canine mammary tumors: a multivariate study of 202 consecutive cases, Vet Pathol, 30, 20, 10.1177/030098589303000103 De Matos, 2007, E-cadherin, beta-catenin, invasion and lymph node metastases in canine malignant mammary tumours, APMIS, 115, 327, 10.1111/j.1600-0463.2007.apm_544.x Gama, 2008, Expression of E-cadherin, P-cadherin and beta-catenin in canine malignant mammary tumours in relation to clinicopathological parameters, proliferation and survival, Vet J, 117, 45, 10.1016/j.tvjl.2007.05.024 Matos, 2006, E-cadherin expression in canine malignant mammary tumours: relationship to other clinico-pathological variables, J Comp Pathol, 134, 182, 10.1016/j.jcpa.2005.10.004 Paredes, 2007, P-cadherin expression in breast cancer: a review, Breast Cancer Res, 9, 214, 10.1186/bcr1774 Paredes, 2005, P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation, Clin Cancer Res, 11, 5869, 10.1158/1078-0432.CCR-05-0059 Gama, 2004, P-cadherin expression in canine mammary tissues, J Comp Pathol, 130, 13, 10.1016/S0021-9975(03)00064-1 Burness, 2010, Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker?, Cancer J, 16, 23, 10.1097/PPO.0b013e3181d24fc1 Foley, 2010, EGFR signaling in breast cancer: bad to the bone, Semin Cell Dev Biol, 21, 951, 10.1016/j.semcdb.2010.08.009 Gama, 2009, Immunohistochemical expression of Epidermal Growth Factor Receptor (EGFR) in canine mammary tissues, Res Vet Sci, 87, 432, 10.1016/j.rvsc.2009.04.016 Rutteman, 1994, Expression of epidermal growth factor receptor (EGFR) in non-affected and tumorous mammary tissue of female dogs, Breast Cancer Res Treat, 30, 139, 10.1007/BF00666057 Sorenmo, 2003, Canine mammary gland tumors, Vet Clin North Am Small Anim Pract, 33, 573, 10.1016/S0195-5616(03)00020-2 Jemal, 2007, Cancer statistics, 2007, CA Cancer J Clin, 57, 43, 10.3322/canjclin.57.1.43 Owen, 1979, A comparative study of canine and human breast cancer, Invest Cell Pathol, 2, 257 1999 Khanna, 2005, Modeling metastasis in vivo, Carcinogenesis, 26, 513, 10.1093/carcin/bgh261 Venkitaraman, 2002, Cancer susceptibility and the functions of BRCA1 and BRCA2, Cell, 108, 171, 10.1016/S0092-8674(02)00615-3 Millau, 2009, P53 transcriptional activities: a general overview and some thoughts, Mutat Res, 681, 118, 10.1016/j.mrrev.2008.06.002 Olson, 2007, Using the canine genome to cure cancer and other diseases, Theriogenology, 68, 378, 10.1016/j.theriogenology.2007.04.016 Chang, 2009, Evaluation of hormone receptor expression for use in predicting survival of female dogs with malignant mammary gland tumors, J Am Vet Med Assoc, 235, 391, 10.2460/javma.235.4.391 Shyamala, 2002, Cellular expression of estrogen and progesterone receptors in mammary glands: regulation by hormones, development and aging, J Steroid Biochem Mol Biol, 80, 137, 10.1016/S0960-0760(01)00182-0 Pinho, 2007, Sialyl Lewis x expression in canine malignant mammary tumours: correlation with clinicopathological features and E-Cadherin expression, BMC Cancer, 7, 124, 10.1186/1471-2407-7-124 de Oliveira, 2010, Coordinated expression of galectin-3 and galectin-3-binding sites in malignant mammary tumors: implications for tumor metastasis, Glycobiology, 20, 1341, 10.1093/glycob/cwq103 Pinho, 2009, Role of E-cadherin N-glycosylation profile in a mammary tumor model, Biochem Biophys Res Commun, 379, 1091, 10.1016/j.bbrc.2009.01.024 Rowell, 2011, Dog models of naturally occurring cancer, Trends Mol Med, 17, 380, 10.1016/j.molmed.2011.02.004 Khanna, 2009, Guiding the optimal translation of new cancer treatments from canine to human cancer patients, Clin Cancer Res, 15, 5671, 10.1158/1078-0432.CCR-09-0719 Paoloni, 2008, Translation of new cancer treatments from pet dogs to humans, Nat Rev Cancer, 8, 147, 10.1038/nrc2273 Mack, 2006, Clinical trials going to the dogs: canine program to study tumor treatment, biology, J Natl Cancer Inst, 98, 161, 10.1093/jnci/djj061 Thamm, 2010, Preclinical investigation of PEGylated tumor necrosis factor alpha in dogs with spontaneous tumors: phase I evaluation, Clin Cancer Res, 16, 1498, 10.1158/1078-0432.CCR-09-2804 London, 2003, Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies, Clin Cancer Res, 9, 2755 Ullrich, 1990, Signal transduction by receptors with tyrosine kinase activity, Cell, 61, 203, 10.1016/0092-8674(90)90801-K Griffin, 2001, The biology of signal transduction inhibition: basic science to novel therapies, Semin Oncol, 28, 3, 10.1016/S0093-7754(01)90097-1 De Vico, 2005, Spontaneous tumours of pet dog as models for human cancers: searching for adequate guidelines, Riv Biol, 98, 279 Hahn, 1994, Naturally occurring tumors in dogs as comparative models for cancer therapy research, In Vivo, 8, 133 Porrello, 2006, Oncology of companion animals as a model for humans. an overview of tumor histotypes, J Exp Clin Cancer Res, 25, 97 Gordon, 2009, The Comparative Oncology Trials Consortium: using spontaneously occurring cancers in dogs to inform the cancer drug development pathway, PLoS Med, 6, e1000161, 10.1371/journal.pmed.1000161